Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients

Journal of the Society for Gynecologic Investigation

Volumn 5, Issue 2, 1998, Pages 102-107

  Schöndorf, Thomas ^a   Engel, Heike ^a   Kurbacher, Christian M ^a   Brenne, Ursula ^a   Kolhagen, Hannelore ^a   Göhring, Uwe Jochen ^a   Scharl, Anton ^a   Mallmann, Peter ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Immunotherapy; Ovarian cancer; TILs

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CELLULAR IMMUNITY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; OVARY CANCER; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-4; KILLER CELLS, NATURAL; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 0032030587     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(97)00112-3     Document Type: Article

References (37)

1. 1. Mallmann P, Krebs D. Generation and activation of tumor-infiltrating lymphocytes for lymphokine-activated killer cell therapy (LAK-TIL's Therapy) in patients with disseminated breast and ovarian cancer. Gynäkol Geburtshilfl Rundsch 1995; 35(Suppl 1):161-5.
2. 2. Freedman RS, Edwards CL, Kavangh JJ, et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial. J Immunother Emphasis Tumor Immunol 1994;16: 198-210.
3. 3. Freedman RS, Platsoucas CD. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Cancer Treat Res 1996;82:115-46.
4. 4. Freedman RS, Tomasovic B, Templin S, et al. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Meth 1994;167:145-60.
5. 5. Mallmann P. Autologous tumor-cell vaccination and lymphokine-activated tumor-infiltrating lymphocytes (LAK-TIL's). Hybridoma 1993;12:559-66.
6. 6. Melioli G, Ratto GB, Ponte M, et al. Treatment of stage IIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Immunother Emphasis Tumor Immunol 1996;19: 224-30.
7. 7. Arienti F, Belli F, Rivoltini L, et al. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol Immunother 1993;36:315-22.
8. 8. Kim HJ, Heo DS, Suh CI, Kim HT, Bang YJ, Kim NK. In vitro generation of immune effector cells from tumor-associated lymphocytes of human gastric cancer. Anticancer Res 1995;15:1247-56.
9. 9. Donnerstag B, Schröder W, Hoos P, Oltrogge JB, Trager L, Bender HG. Interactions between tumor cells and tumor infiltrating lymphocytes in human ovarian carcinoma. Clin Exp Obstet Gynecol 1994;21:153-9.
10. 10. Bateman WJ, Donnellan I, Fraser IA, Wong LS, Morris AG. Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon-γ. Cancer Immunol Immunother 1995;41:61-7.
11. 11. Facchetti P, Prigione I, Ghiotto F, Tasso P, Garaventa A, Pistoia V. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility complex-negative human tumour: Neuroblastoma. Cancer Immunol Immunother 1996;42:170-8.
12. 12. Freedman RS, Ioannides CG, Mathioudakis G, Platsoucas CD. Novel immunologic strategies in ovarian carcinoma. Am J Obstet Gynecol 1992;167:1470-8.
13. 13. Elsässer-Beile U, Wetterauer U, Schultze-Seemann W, Gallati H, Schulte Mönting J, von Kleist S. Analysis of the immune reactivity of infiltrating and peripheral lymphocytes from patients with renal cell carcinoma by measuring cytokine secretion. Cancer Immunol Immunother 1996;42:93-8.
14. 14. Coventry BJ, Weeks SC, Heckford SE, Sykes PJ, Bradley J, Skinner JM. Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma. J Immunol 1996;156:3486-92.
15. 15. Karimine N, Nanbara S, Arinaga S, Asoh T, Ueo H, Akiyoshi T. Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients. J Surg Oncol 1994;55:179-85.
16. 16. Schöndorf T, Engel H, Lindemann C, Kolhagen H, von Rücker AA, Mallmann P. Cellular characteristics of peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gynaecological tumors. Cancer Immunol Immunother 1997;44: 88-96.
17. 17. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: Specific immune reactivity detected by measuring cytokine secretion. J Immunother 1992;12:1-12.
18. 18. Yanelli JR, Hyatt C, McConnell S, et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. Int J Cancer 1996;65:413-21.
19. 19. Young MRI, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer. Int J Cancer 1996;67:333-8.
20. + T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol Immunother 1995;40:1-9.
21. 21. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 1996;105:344-52.
22. 22. Severin T, Müller B, Giese G, et al. pH-dependent LAK cell cytotoxicity. Tumor Biol 1994;15:304-10.
23. + T helper subsets in human melanoma. Surgery 1995;117:365-72.
24. 24. Plaisance S, Rubinstein E, Alileche A, et al. Human melanoma cells express a functional interleukin-2 receptor. Int J Cancer 1993;55:164-70.
25. 25. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD, Freeman SM. Tumor-host interaction: Analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 1997;28:321-31.
26. 26. Alexander JP, Kudoh S, Melsop KA, et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 1993;53:1380-7.
27. 27. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258: 1795-8.
28. 28. McCoy JP Jr, Overton WR. Quality control in flow cytometry for diagnostic pathology: II. A conspectus of reference ranges for lymphocyte immunophenotyping. Cytometry 1994;18:129-39.
29. 29. O'Garra A, Murphy K. Role of cytokines in development of Th1 and Th2 cells. In: Romagnani S, ed. Th1 and Th2 cells in health and disease. Chemical Immunology Volume 63. HBasel, Switzerland: Karger AG, 1996:1-13.
30. 30. Whiteside TL, Parmiani G. Tumor-infiltrating lymphocytes: Their phenotype, functions and clinical use. Cancer Immunol Immunother 1994;39:15-21.
31. 31. Baxevanis CN, Dedoussis GVZ, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 1994;74: 1275-82.
32. 32. Mantovani G, Macciò A, Versace R, et al. Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. J Mol Med 1995; 73:409-16.
33. 33. Wang Q, Redovan C, Tubbs R, et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer 1995;61:780-5.
34. 34. Kharkevitch DD, Seito D, Balch GC, Maeda T, Balch CM, Itoh K. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Int J Cancer 1994;58:317-23.
35. 35. Camp BJ, Dyhrman ST, Memoli VA, Mott LA, Barth RJ Jr. In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oncol 1996;3:176-84.
36. 36. Vitolo D, Zerbe T, Kanbour A, Dahl C, Herberman RB, Whiteside TL. Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 1992;51:573-80.
37. 37. Rabinowich H, Suminami Y, Reichert TE, et al. Expression of cytokine genes or proteins and signalling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996;68:276-84.